Genetically modified live attenuated parasites as vaccines for leishmaniasis

Indian Journal of Medical Research

Volumn 123, Issue 3, 2006, Pages 455-466

  Selvapandiyan, Angamuthu ^a   Duncan, Robert ^a   Debrabant, Alain ^a   Lee, Nancy ^a   Sreenivas, G ^a   Salotra, Poonam ^b   Nakhasi, Hira L ^a  

^a Division of Viral Products   (United States)

^b SAFDARJUNG HOSPITAL CAMPUS   (India)

Author keywords

Animal model; Leishmania; Leishmaniasis; Live attenuated parasite

Indexed keywords

ANTILEISHMANIAL AGENT; BCG VACCINE; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; FUCOSE MANNOSE LIGAND VACCINE; INACTIVATED VACCINE; LEISHMANIA VACCINE; LIVE VACCINE; PARASITE ANTIGEN; PROTOZOAL VACCINE; RECOMBINANT ANTIGEN; RECOMBINANT LEIF PROTEIN; RECOMBINANT PROTEIN; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

BLOOD TRANSFUSION; CELL LYSATE; CLINICAL TRIAL; CONSENSUS; DEVELOPING COUNTRY; DRUG TREATMENT FAILURE; ENDEMIC DISEASE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; LEISHMANIASIS; MORBIDITY; MORTALITY; NONHUMAN; PARASITE VIRULENCE; PSYCHODIDAE; PUBLIC HEALTH; REVIEW; SKIN LEISHMANIASIS; SPECIES DIFFERENCE; TRANSGENIC ORGANISM; TROPIC CLIMATE; VISCERAL LEISHMANIASIS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; GENETIC TECHNIQUES; HUMANS; LEISHMANIA; LEISHMANIASIS; MODELS, GENETIC; PROTOZOAN VACCINES;

EID: 33745199386     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27 : 305-18.
2. Rivas L, Moreno J, Canavate C, Alvar J. Virulence and disease in leishmaniasis: what is relevant for the patient? Trends Parasitol 2004; 20 : 297-301.
3. Desjeux P. Human leishmaniasis: epidemiology and public health aspects. World Health Stat Q 1992; 45 : 267-75.
4. Herwaldt BL. Leishmaniasis. Lancet 1999; 354 : 1191-9.
5. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 2001; 14 : 229-43.
6. Gaskin AA, Schantz P, Jackson J, Birkenheuer A, Tomlinson L, Gramiccia M, et al. Visceral leishmaniasis in a New York foxhound kennel. J Vet Intern Med 2002; 16 : 34-44.
7. Aronson N, Coleman R, Coyne P, Rowton E, Hack D, Polhemus M, et al. Cutaneous leishmaniasis in U.S. military personnel - Southwest/Central Asia, 2002-2003. MMWR Wkly 2003; 52 : 1009-12.
8. American Association of Blood Bankers. Deferral for risk of leishmaniasis exposure. AABB Bull 2003; 03-14.
9. Giger U, Oakley DA, Owens SD, Schantz P. Leishmania donovani transmission by packed RBC transfusion to anemic dogs in the United States. Transfusion 2002; 42 : 381-3.
10. Palatnik-de-Sousa CB, Paraguai-de-Souza E, Gomes EM, Soares-Machado FC, Luz KG, Borojevic R. Transmission of visceral leishmaniasis by blood transfusion in hamsters. Braz J Med Biol Res 1996; 29 : 1311-5.
11. Molyneux D, Killick-Kendrick R. Morphology, ultrastructure and life cycles. In: Peters W, Killick-Kendrick R, editors. The leishmaniasis in biology and medicine. London: Academic Press; 1987 p. 121-76.
12. Goyard S, Segawa H, Gordon J, Showalter M, Duncan R, Turco SJ, et al. An in vitro system for developmental and genetic studies of Leishmania donovani phosphoglycans. Mol Biochem Parasitol 2003; 130 : 31-42.
13. Debrabant A, Joshi MB, Pimenta PFP, Dwyer DM. Generation of Leishmania donovani axenic amastigotes: their growth and biological characteristics. Int J Parasitol 2004; 34 : 205-17.
14. Debrabant A, Lee N, Pogue GP, Dwyer DM, Nakhasi HL. Expression of calreticulin P-domain results in impairment of secretory pathway in Leishmania donovani and reduced parasite survival in macrophages. Int J Parasitol 2002; 32 : 1423-34.
15. Selvapandiyan A, Debrabant A, Duncan R, Muller J, Salotra P, Sreenivas G, et al. Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania. J Biol Chem 2004; 279 : 25703-10.
16. Davis AJ, Murray HW, Handman, E. Drugs against leishmaniasis: a synergy of technology and partnerships. Trends Parasitol 2004; 20 : 73-6.
17. Croft SL, Coombs GH. Leishmaniasis - current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003; 19 : 502-8.
18. Handman, E. Leishmania vaccines: Old and New. Parasitol Today 1997; 13 : 236-8.
19. McMahon-Pratt D, Alexander J. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniasis or the visceral disease? Immunol Rev 2004; 201 : 206-24.
20. Awasthi A, Mathur RK, Saha B. Immune response to Leishmania infection. Indian J Med Res 2004; 119 : 238-58.
21. Kharazmi A, Kemp K, Ismail A, Gasim S, Gaafar A, Kurtzhals JA, et al. T-cell response in human leishmaniasis. Immunol Lett 1999; 65 : 105-8.
22. Gumy A, Louis JA, Launois P. The murine model of infection with Leishmania major and its importance for the deciphering of mechanisms underlying differences in Th cell differentiation in mice from different genetic backgrounds. Int J Parasitol 2004; 34 : 433-44.
23. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994; 263 : 235-7.
24. Mattner F, Magram J, Ferrante J, Launois P, Di Padova K, Behin R, et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 1996; 26 : 1553-9.
25. Solbach W, Laskay T. The host response to Leishmania infection. Adv Immunol 2000; 74 : 275-317.
26. Jones D, Elloso MM, Showe L, Williams D, Trinchieri G, Scott, P. Differential regulation of the interleukin-12 receptor during the innate immune response to Leishmania major. Infect Immun 1998; 66 : 3818-24.
27. Launois P, Ohteki T, Swihart K, MacDonald HR, Louis JA. In susceptible mice, Leishmania major induces very rapid interleukin-4 production by CD4+ T cells, which are NK1.1. Eur J Immunol 1995; 25 : 3298-307.
28. Alexander J, Satoskar AR, Russell DG. Leishmania species: models of intracellular parasitism. J Cell Sci 1999; 112 : 2993-3002.
29. Alexander J, Brombacher F, McGachy HA, McKenzie AN, Walker W, Carter, KC. An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection. Eur J Immunol 2002; 32 : 2923-33.
30. Mohrs M, Holscher C, Brombacher F. Interleukin-4 receptor alpha-deficient BALB/c mice show an unimpaired T helper 2 polarization in response to Leishmania major infection. Infect Immun 2000; 68 : 1773-80.
31. Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP. IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 2001; 31 : 2848-56.
32. Mathur RK, Awasthi A, Wadhone P, Ramanamurthy B, Saha B. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat Med 2004; 10 : 540-4.
33. Gicheru MM, Olobo JO, Anjili CO, Orago AS, Modabber F, Scott P. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect Immun 2001; 69 : 245-51.
34. Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, Klinman DM. CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol 2002; 168 : 1659-63.
35. Amaral VF, Teva A, Oliveira-Neto MP, Silva AJ, Pereira MS, Cupolillo E, et al. Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease. Mem Inst Oswaldo Cruz 2002; 97 : 1041-8.
36. Khalil EA, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, Musa B, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomized, double-blind, BCG-controlled trial in Sudan. Lancet 2000; 356 : 1565-9.
37. Sharifi I, FeKri AR, Aflatonian MR, Khamesipour A, Nadim A, Mousavi MR, et al. Randomized vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998; 351 : 1540-3.
38. Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, Ghassemi RL, et al. A randomized, double blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 1999; 17 : 466-72.
39. da Silva VO, Borja-Cabrera GP, Correia Pontes NN, de Souza EP, Luz KG, Palatnik M, et al. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (Sao Goncalo do Amaranto, RN). Vaccine 2000; 19 : 1082-92.
40. Russell DG, Alexander J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J Immunol 1988; 140 : 1274-9.
41. Mendonca SC, Russell DG, Coutinho SG. Analysis of the human T cell responsiveness to purified antigens of Leishmania: lipophosphoglycan (LPG) and glycoprotein 63 (gp 63). Clin Exp Immunol 1991; 83 : 472-8.
42. Skeiky YA, Kennedy M, Kaufman D, Borges MM, Guderian JA, Scholler JK, et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J Immunol 1998; 161 : 6171-9.
43. Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K, Crane RT, et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 2002; 20 : 3292-303.
44. Gurunathan S, Wu CY, Freidag BL, Seder RA. DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol 2000; 12 : 442-7.
45. Walker PS, Scharton-Kersten T, Rowton ED, Hengge U, Bouloc A, Udey MC, et al. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum Gene Ther 1998; 9 : 1899-907.
46. Sjolander A, Baldwin TM, Curtis JM, Handman E. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis. J Immunol 1998; 160 : 3949-57.
47. Iborra S, Soto M, Carrion J, Alonso C, Requena JM. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniasis. Vaccine 2004; 22 : 3865-76.
48. Ghosh A, Labrecque S, Matlashewski G. Protection against Leishmania donovani infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. Vaccine 2001; 19 : 3169-78.
49. Melby PC, Ogden GB, Flores HA, Zhao W, Geldmacher C, Biediger NM, et al. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect Immun 2000; 68 : 5595-602.
50. Valenzuela JG, Belkaid Y, Garfield MK, Mendez S, Kamhawi S, Rowton ED, et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J Exp Med 2001; 194 : 331-42.
51. Morris RV, Shoemaker CB, David JR, Lanzaro GC, Titus RG. Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J Immunol 2001; 167 : 5226-30.
52. Krieg, AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20 : 709-60.
53. Verthelyi D, Klinman DM. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clin Immunol 2003; 109 : 64-71.
54. Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004; 199 : 201-16.
55. Handman, E. Protective saliva: a novel approach to a Leishmania vaccine. Trends Parasitol 2001; 17 : 513-4.
56. Titus RG, Gueirps-Filho FJ, de Freitas LA, Beverley SM. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci USA 1995; 92 : 10267-71.
57. Streit JA, Recker TJ, Filho FG, Beverley SM, Wilson ME. Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms. J Immunol 2001; 166 : 1921-9.
58. Salisbury JL. Centrosomes: Sfilp and centrin unravel a structural riddle. Curr Biol 2004; 14 : R27-9.
59. Selvapandiyan A, Duncan R, Debrabant A, Bertholet S, Sreenivas G, Negi NS, et al. Expression of a mutant form of Leishmania donovani centrin reduces the growth of the parasite. J Biol Chem 2001; 276 : 43253-61.
60. Antoniazi S, Lima HC, Cruz AK. Overexpression of miniexon gene decreases virulence of Leishmania major in BALB/c mice in vivo. Mol Biochem Parasitol 2000; 107 : 57-69.
61. Plewes KA, Barr SD, Gedamu L. Iron superoxide dismutases targeted to the glycosomes of Leishmania chagasi are important for survival. Infect Immun 2003; 71 : 5910-20.
62. Capecchi MR. Altering the genome by homologous recombination. Science 1989; 244 : 1288-92.
63. Cruz A, Coburn CM, Beverley SM. Double targeted gene replacement for creating null mutants. Proc Natl Acad Sci USA 1991; 88 : 7170-4.
64. Alexander J, Coombs GH, Mottram JC. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J Immunol 1998; 161 : 6794-801.
65. Burchmore RJ, Rodriguez-Contreras D, McBride K, Merkel P, Barrett MP, Modi G, et al. Genetic characterization of glucose transporter function in Leishmania mexicana. Proc Natl Acad Sci USA 2003; 100 : 3901-6.
66. Joshi PB, Sacks DL, Modi G, McMaster WR. Targeted gene deletion of Leishmania major genes encoding developmental stage-specific leishmanolysin (GP63). Mol Microbiol 1998; 27 : 519-30.
67. Joshi PB, Kelly BL, Kamhawi S, Sacks DL, McMaster WR. Targeted gene deletion in Leishmania major identifies leishmanolysin (GP63) as a virulence factor. Mol Biochem Parasitol 2002; 120 : 33-40.
68. Spath GF, Epstein L, Leader B, Singer SM, Avila HA, Turco SJ, et al. Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major. Proc Natl Acad Sci USA 2000; 97 : 9258-63.
69. Spath GF, Lye LF, Segawa H, Sacks DL, Turco SJ, Beverley SM. Persistence without pathology in phosphoglycandeficient Leishmania major. Science 2003; 301 : 1241-3.
70. Uzonna JE, Spath GF, Beverley SM, Scott P. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J Immunol 2004; 172 : 3793-7.
71. Souza AE, Bates PA, Coombs GH, Mottram JC. Null mutants for the lmcpa cysteine proteinase gene in Leishmania mexicana. Mol Biochem Parasitol 1994; 63 : 213-20.
72. Mottram JC, Souza AE, Hutchison JE, Carter R, Frame MJ, Coombs GH. Evidence from disruption of the lmcpb gene array of Leishmania mexicana that cysteine proteinases are virulence factors. Proc Natl Acad Sci USA 1996; 93 : 6008-13.
73. Papadopoulou B, Roy G, Breton M, Kundig C, Dumas C, Fillion I, et al. Reduced infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect Immun 2002; 70 : 62-8.
74. Sacks DL, Modi G, Rowton E, Spath G, Epstein L, Turco SJ, et al. The role of phosphoglycans in Leishmania-sand fly interactions. Proc Natl Acad Sci USA 2000; 97 : 406-11.
75. Spath GF, Garraway LA, Turco SJ, Beverley SM. The role(s) of lipophosphoglycan (LPG) in the establishment of Leishmania major infections in mammalian hosts. Proc Natl Acad Sci USA 2003; 100 : 9536-41.
76. Bart G, Frame MJ, Carter R, Coombs GH, Mottram JC. Cathepsin B-like cysteine proteinase-deficient mutants of Leishmania mexicana. Mol Biochem Parasitol 1997; 88 : 53-61.
77. Zhang WW, Matlashewski G. Characterization of the A2-A2rel gene cluster in Leishmania donovani: involvement of A2 in visceralization during infection. Mol Microbiol 2001; 309 : 935-48.
78. Spath GF, Lye LF, Segawa H, Turco SJ, Beverley SM. Identification of a compensatory mutant (Ipg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies. Infect Immun 2004; 72 : 3622-7.
79. Belkaid Y, Mendez S, Lira R, Kadambi N, Milon G, Sacks D. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. J Immunol 2000; 165 : 969-77.
80. Belkaid Y, Kamhawi S, Modi G, Valenzuela J, Noben-Trauth N, Rowton E, et al. Development of a natural model of cutaneous leishmaniasis: powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis. J Exp Med 1998; 188 : 1941-53.
81. Freidag BL, Mendez S, Cheever AW, Kenney RT, Flynn B, Sacks DL, et al. Immunological and pathological evaluation of rhesus macaques infected with Leishmania major. Exp Parasitol 2003; 103 : 160-8.
82. Duncan R, Salotra P, Goyal N, Akopyants N, Beverley S, Nakhasi, H. The application of gene expression microarray technology to kinetoplastid pathogenesis. Curr Mol Med 2004; 4 : 611-21.
83. Pollack JR, Peron CM, Alizadeh AA, Eisen MB, Pergamenschikov A, Williams CF, et al. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 1999; 23 : 41-6.